174 related articles for article (PubMed ID: 9063693)
1. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.
Siegmund B; Eigler A; Moeller J; Greten TF; Hartmann G; Endres S
Eur J Pharmacol; 1997 Feb; 321(2):231-9. PubMed ID: 9063693
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.
Eigler A; Siegmund B; Emmerich U; Baumann KH; Hartmann G; Endres S
J Leukoc Biol; 1998 Jan; 63(1):101-7. PubMed ID: 9469479
[TBL] [Abstract][Full Text] [Related]
3. Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-alpha synthesis.
Greten TF; Sinha B; Haslberger C; Eigler A; Endres S
Eur J Pharmacol; 1996 Mar; 299(1-3):229-33. PubMed ID: 8901027
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids.
Sinha B; Semmler J; Eisenhut T; Eigler A; Endres S
Eur J Immunol; 1995 Jan; 25(1):147-53. PubMed ID: 7843225
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
Seldon PM; Barnes PJ; Giembycz MA
Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
[TBL] [Abstract][Full Text] [Related]
6. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
7. Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.
Eigler A; Matschke V; Hartmann G; Erhardt S; Boyle D; Firestein GS; Endres S
J Leukoc Biol; 2000 Jul; 68(1):97-103. PubMed ID: 10914495
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of tumour necrosis factor-alpha in tissue culture of rat caecum: lack of suppression by phosphodiesterase inhibitors and prostanoids.
Greten TF; Moeller J; Feldmeier H; Eigler A; Endres S
Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):679-84. PubMed ID: 8853258
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor.
Prabhakar U; Lipshutz D; Bartus JO; Slivjak MJ; Smith EF; Lee JC; Esser KM
Int J Immunopharmacol; 1994 Oct; 16(10):805-16. PubMed ID: 7843852
[TBL] [Abstract][Full Text] [Related]
10. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
11. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
[TBL] [Abstract][Full Text] [Related]
12. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis.
Eigler A; Greten TF; Sinha B; Haslberger C; Sullivan GW; Endres S
Scand J Immunol; 1997 Feb; 45(2):132-9. PubMed ID: 9042424
[TBL] [Abstract][Full Text] [Related]
13. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.
Semmler J; Wachtel H; Endres S
Int J Immunopharmacol; 1993 Apr; 15(3):409-13. PubMed ID: 8505151
[TBL] [Abstract][Full Text] [Related]
14. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication.
Angel JB; Saget BM; Walsh SP; Greten TF; Dinarello CA; Skolnik PR; Endres S
AIDS; 1995 Oct; 9(10):1137-44. PubMed ID: 8519449
[TBL] [Abstract][Full Text] [Related]
15. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages.
Kambayashi T; Jacob CO; Zhou D; Mazurek N; Fong M; Strassmann G
J Immunol; 1995 Nov; 155(10):4909-16. PubMed ID: 7594495
[TBL] [Abstract][Full Text] [Related]
16. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
[TBL] [Abstract][Full Text] [Related]
17. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
[TBL] [Abstract][Full Text] [Related]
18. Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.
Yoshimura T; Kurita C; Nagao T; Usami E; Nakao T; Watanabe S; Kobayashi J; Yamazaki F; Tanaka H; Nagai H
Gen Pharmacol; 1997 Oct; 29(4):633-8. PubMed ID: 9352314
[TBL] [Abstract][Full Text] [Related]
19. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages.
Schade FU; Schudt C
Eur J Pharmacol; 1993 Jan; 230(1):9-14. PubMed ID: 8381357
[TBL] [Abstract][Full Text] [Related]
20. The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide.
Greten TF; Eigler A; Sinha B; Moeller J; Endres S
Int J Immunopharmacol; 1995 Jul; 17(7):605-10. PubMed ID: 8586489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
